Pretreatment serum interleukin-12 levels in predicting sustained virological response among hepatitis C patients following Pegylated Interferon-α2β plus Ribavirin treatment

Annals of Gastroenterology

Volumn 26, Issue 3, 2013, Pages 249-254

  Perperas, Antony ^a   Karagiannakis, Demetris ^b   Anagnostopoulos, George ^b   Tsirogiannis, Alexandra ^c   Panagiotakos, Dimosthenis ^d   Papadopoulos, Savvas ^a   Tsagkaris, Manolis ^e   Papasteriades, Chryssa ^c   Manolakopoulos, Spilios ^f  

^a HYGEIA HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d HAROKOPIO UNIVERSITY   (Greece)

^e SISMANOGLIO HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cytokine; Dendritic cells; Hepatitis C; Interleukin 12; Pegylated interferon 2 ; T helper cells

Indexed keywords

INTERLEUKIN 12; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER FUNCTION TEST; MALE; PREDICTION; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84879427970     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
2. Cornberg M, Razaui H, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 (Suppl 2):30-60.
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
4. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
5. Romagnani S, Parronchi F, D'Elios MM, et al. An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997;113:153-156.
6. Gramenzi A, Andreone P, Loggi E, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat 2005;12:525-530.
7. Darling JM, Wright TL. Immune responses in hepatitis C: is virus or host the problem? Curr Opin Infect Dis 2004;17:193-198.
8. Sarih M, Bouchrit N, Benslimane A. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virus infection. Immunol Lett 2000;74:117-120.
9. Sobue S, Nomura T, Ishikawa T, et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J Gastroenterol 2001;36:544-551.
10. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
11. Kanto T, Inoue M, Miyatake H, et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 2004;190:1919-1926.
12. Waggoner SN, Hall CH, Hahn YS. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 2007;82:1407-1419.
13. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A 1991;88:3392-3396.
14. Meyer-Olson D, Shoukry NH, Brady KW, et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med 2004;200:307-319.
15. Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol 2005;79:10514-10527.
16. Li W, Li J, Tyrrell DL, Agrawal B. Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities. J Gen Virol 2006;87(Pt 1):61-72.
17. Della Bella S, Crosignani A, Riva A, et al. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology 2007;121:283-292.
18. Miyatake H, Kanto T, Inoue M, et al. Impaired ability of interferonalpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J Viral Hepat 2007;14:404-412.
19. Tamir A, Jordan WJ, Ritter M, et al. Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. Clin Exp Immunol 2005;142:471-480.
20. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 2008;47:306-320.
21. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36(5 Suppl 1):S3-S20.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
23. Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002;195:1507-1512.
24. Anthony DD, Yonkers NL, Post AB, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 2004;172:4907-4916.
25. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-1184.
26. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-827, 827. e1.
27. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005;2:92-100.
28. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM. Sustained IL-12 signaling is required for Th1 development. J Immunol 2004;172:61-69.
29. Yoneda S, Umemura T, Katsuyama Y, et al.; Nagano Interferon Treatment Research Group. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011;203:1087-1095.
30. Quiroga JA, Martin J, Navas S, Carreno V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998;178:247-251.